Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors

Dateline City:

KENILWORTH, N.J. & HOUSTON

Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types

KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
The University of Texas MD Anderson Cancer Center today announced that
they have entered into a strategic clinical research collaboration to
evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®
(pembrolizumab), in combination with other treatments, such as
chemotherapy, radiation therapy and/or novel antitumor medicines.

Language:

English

Contact:

Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orMD Anderson Media Relations:Ron Gilmore, [e-mail]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - August 13, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news